Deal Watch: Alnylam/Dicerna Pact Addresses IP Questions Around Primary Hyperoxaluria Programs
Executive Summary
The two RNAi firms cross-license IP from their PH programs, while also partnering on a rare liver disease candidate. GSK invests $250m in Vir and will help to advance its antibody candidates for COVID-19.
You may also be interested in...
Alnylam Shows Efficacy, Safety With Lumasiran In Vulnerable Pediatric Patients
The top-line data in the ultra-rare disease are also the first to demonstrate safety and efficacy of an RNAi therapy in patients six years and younger.
Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Alnylam’s Full Lumasiran Dataset Seen As Confirming Approvability
Building on data first reported last December, lumasiran appears on pace for approval by the December 2020 action date, but Dicerna still may show its drug is best-in-class.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports